08
OCT
2026

Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production

Posted By :
Comments : Off
BETHESDA, Md., October 8, 2026 — Northwest Biotherapeutics (OTCQB:NWBO) (the “Company” or “NWBio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, and the UK National Health Service Blood and Transplant (“NHSBT”) announce that they have entered into a collaboration, as the culmination of months of joint efforts by the parties, to support production of the Company’s...
Read More
06
OCT
2026

Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference

Posted By :
Comments : Off
BETHESDA, Md., October 6, 2026 — Northwest Biotherapeutics (OTCQB:NWBO) (the “Company” or “NWBio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, the Company’s Chief Technical Officer, will be making an invited keynote presentation entitled “Harnessing Immunity: A Personalised, Multi-Target Approach to Cancer” at the annual UK National...
Read More
06
AUG
2026

Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company

Posted By :
Comments : Off
SPIMACO is One of the Largest Saudi Pharma Companies and a Leader in 21 Markets Across the MENA Region BETHESDA, Md., August 6, 2026 — Northwest Biotherapeutics (OTCQB:NWBO) (the “Company” or “NWBio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has entered into a non-binding Memorandum of Understanding (MOU) with the Saudi Pharmaceutical Industries and...
Read More
08
JUL
2026

Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Posted By :
Comments : Off
Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely Underestimated BETHESDA, Md., July 8, 2026 — Northwest Biotherapeutics (OTCQB:NWBO) (the “Company” or “NWBio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the Company’s Chief Technical Officer, Dr. Marnix Bosch, presented updated...
Read More
02
JUL
2026

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

Posted By :
Comments : Off
BETHESDA, Md., July 2, 2026 — Northwest Biotherapeutics (OTCQB:NWBO) (the “Company” or “NWBio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, the Company’s Chief Technical Officer, will be making a scientific presentation entitled “DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses” at the 2026 Annual...
Read More